AtriCure valuation "extremely compelling" at current levels, says Barrington
Barrington finds shares of AtriCure "extremely compelling" following the resolution with the Department of Justice and the company's Q3 results. The firm reiterates an Outperform rating on the stock with a $10 price target. :theflyonthewall.com
News For ATRC From The Last 14 Days
Check below for free stories on ATRC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
